IRD
Opus Genetics, Inc.
5.00$
-1.9%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | -3,288.6% | 35.9% | -5.8% | -232.7% | -248.3% | |
| – | – | 0.7% | 0.0% | 0.0% | 0.1% | 0.4% | |
| – | – | 325.0% | 4.5% | 18.4% | 30.6% | 23.9% | |
| – | – | 30.7% | -13.9% | 21.4% | 28.1% | -15.2% | |
| – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| – | – | -17.0% | – | – | 11.0% | – | |
| – | – | – | – | 0.0% | -0.7% | -1.1% | |
| – | – | 91.3% | -1.4% | 0.0% | – | – | |
| – | – | 4,686.8% | 9.5% | 47.1% | 38.1% | 352.4% | |
| – | – | 1,381.2% | 45.4% | 41.3% | -183.6% | 104.0% | |
| – | – | -3,288.6% | 35.9% | -5.8% | -232.7% | -248.3% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.